Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.
Lisette M PrensK BouwmanP AartsS ArendsKelsey R van StraalenK DudinkBarbara HorváthE P PrensPublished in: The British journal of dermatology (2021)
Survival rates were comparable for adalimumab and infliximab at 12 months, and were mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival.
Keyphrases
- hidradenitis suppurativa
- ulcerative colitis
- rheumatoid arthritis
- juvenile idiopathic arthritis
- free survival
- minimally invasive
- primary care
- healthcare
- coronary artery bypass
- coronary artery disease
- systemic lupus erythematosus
- quality improvement
- atrial fibrillation
- surgical site infection
- patients with inflammatory bowel disease